For postmenopausal patients with ER-positive advanced breast cancer, the orally administered mTOR inhibitor everolimus combined with an AI was recently shown to prolong progression-free survival (PFS) relative to placebo combined with an AI from 2.8 months to 6.9 months (p < 0.001) in the phase 3 BOLERO-2 trial [12]. Here, MTOR is linked to breast carcinoma.